Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - EAEU

EAEU

The Other Vaccines market in the EAEU is expected to achieve a revenue of US$0.37bn by 2024.
It is projected to witness a steady annual growth rate (CAGR 2024-2029) of 9.41%, leading to a market volume of US$0.58bn by 2029.
Among all countries, United States is anticipated to generate the highest revenue in this market, amounting to US$24,730.00m in 2024.
The EAEU has seen a significant increase in demand for other vaccines, driven by a growing awareness of the importance of preventative healthcare.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in EAEU has been experiencing steady growth in recent years.

Customer preferences: There is a growing demand for vaccines in the EAEU region due to the increase in public health awareness and the need for disease prevention. Customers are also becoming more informed about the benefits of vaccination and are willing to pay for the necessary vaccines.

Trends in the market: The market for Other Vaccines in EAEU is expected to grow due to the increasing number of vaccine-preventable diseases in the region. The demand for vaccines is also being driven by government initiatives to promote vaccination, as well as the growing number of private healthcare providers.

Local special circumstances: The EAEU region is unique in that it consists of countries with vastly different healthcare systems and levels of development. Some countries have well-established healthcare systems with high levels of public health awareness, while others are still developing their healthcare infrastructure and public health initiatives. This creates a complex market landscape for vaccine manufacturers and distributors.

Underlying macroeconomic factors: The economic growth in the EAEU region is also contributing to the growth of the Other Vaccines market. As the region becomes more prosperous, there is a greater demand for healthcare services, including vaccination. Additionally, the increasing prevalence of vaccine-preventable diseases is driving up the demand for vaccines. The regulatory environment in the region is also becoming more favorable for vaccine manufacturers, which is contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.